Related Experiment Video
Updated: Jul 12, 2025
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Parenteral Vancomycin in the Treatment of MRSA-Associated Diabetic Foot Infections: An Unnecessary Risk
Warren S Joseph1, Mark A Kosinski2, Lee C Rogers3
1Arizona College of Podiatric Medicine, Midwestern University, Glendale, AZ, USA.
Abstract:
Diabetic foot infections (DFIs) are a common and costly complication of diabetes. Soft tissue and bone infections in DFIs frequently lead to amputation and/or sepsis which can be costly for both the patient and the healthcare system. Staphylococcus aureus is the most commonly identified causative agent in DFIs, and people with diabetes may have an increased risk of infection with methicillin-resistant Staphylococcus aureus (MRSA). In addition to increased susceptibility to severe infection, MRSA in DFIs is associated with high rates of treatment failure, morbidity, and hospitalization costs meaning appropriate treatment is a high priority. While hospitalized patients are usually treated with intravenous (IV) vancomycin, this can be costly in terms of inpatient stays, staffing costs, and adverse events. For example, vancomycin-associated acute kidney injury not only delays hospital discharge and increases costs but is also a particular concern for patients with diabetes who already have an increased risk of kidney problems. Vancomycin-resistant strains of S. aureus have also been identified, which means that alternative treatment options may need to be explored. Treatment alternatives to IV vancomycin, including oral antibiotics, have been shown to provide similar efficacy, with reduced costs, outpatient or home-based administration, and with fewer serious adverse effects. Although infectious disease specialists often use IV vancomycin alone, or in combination, as a first-line therapeutic option, they are increasingly seeing the value of outpatient or at-home oral antibiotics as an alternative. This manuscript reviews the evidence for true costs of vancomycin therapy for MRSA-associated DFIs and examines the alternatives.
Insights
Diabetic foot infections caused by MRSA are costly. Oral antibiotics offer a cost-effective alternative to IV vancomycin, with similar efficacy and fewer adverse events.
Area of Science:
- Infectious Diseases
- Diabetology
- Pharmacoeconomics
Background:
- Diabetic foot infections (DFIs) are a significant complication of diabetes, often caused by *Staphylococcus aureus*, including methicillin-resistant strains (MRSA).
- MRSA-associated DFIs lead to high morbidity, treatment failures, and substantial healthcare costs, necessitating effective and economical treatment strategies.
- Intravenous (IV) vancomycin is a common treatment but is associated with high costs, prolonged hospital stays, and adverse events like acute kidney injury, particularly concerning in diabetic patients.
Purpose of the Study:
- To review the true costs associated with vancomycin therapy for MRSA-DFIs.
- To examine alternative antibiotic treatments for MRSA-DFIs.
- To evaluate the efficacy and cost-effectiveness of oral antibiotics compared to IV vancomycin.
Main Methods:
- Literature review of studies comparing vancomycin therapy with alternative treatments for MRSA-DFIs.
- Analysis of data on treatment costs, efficacy, adverse events, and administration routes (inpatient vs. outpatient).
- Examination of pharmacoeconomic data related to vancomycin and oral antibiotic regimens.
Main Results:
- IV vancomycin therapy for MRSA-DFIs incurs significant costs due to inpatient stays, staffing, and potential adverse events.
- Oral antibiotic alternatives demonstrate comparable efficacy to IV vancomycin for MRSA-DFIs.
- Outpatient or home-based administration of oral antibiotics offers reduced costs and fewer serious adverse effects compared to IV vancomycin.
Conclusions:
- Oral antibiotics represent a viable and cost-effective alternative to IV vancomycin for treating MRSA-associated DFIs.
- Shifting towards outpatient oral antibiotic therapy can decrease healthcare expenditures and improve patient outcomes.
- Further exploration of alternative treatment strategies is warranted due to rising vancomycin resistance and associated treatment challenges.
Related Concept Videos
01:18Endocarditis III: Medical Management
01:29Endocarditis IV: Nursing Management
01:17Urinary Tract Infection IV: Nursing Management
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Antimicrobial Effectiveness